Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Background
Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer therapy and several FGFR inhibitors have promising results in different tumors but treatment efficiency may still be improved. The clinical use of immune checkpoint blockade (ICB) has resulted in sustained remission for patients.
Main
Although there is limited data linking FGFR inhibitors and immunotherapy, preclinical research suggest that FGF/FGFR signaling is involved in regulating the tumor microenvironment (TME) including immune cells, vasculogenesis, and epithelial-mesenchymal transition (EMT). This raises the possibility that ICB in combination with FGFR-tyrosine kinase inhibitors (FGFR-TKIs) may be feasible for treatment option for patients with dysregulated FGF/FGFR signaling.
Conclusion
Here, we review the role of FGF/FGFR signaling in TME regulation and the potential mechanisms of FGFR-TKI in combination with ICB. In addition, we review clinical data surrounding ICB alone or in combination with FGFR-TKI for the treatment of FGFR-dysregulated tumors, highlighting that FGFR inhibitors may sensitize the response to ICB by impacting various stages of the “cancer-immune cycle”.
Top-30
Journals
|
1
2
3
4
5
|
|
|
International Journal of Molecular Sciences
5 publications, 6.41%
|
|
|
Frontiers in Oncology
5 publications, 6.41%
|
|
|
Frontiers in Immunology
4 publications, 5.13%
|
|
|
Cancers
2 publications, 2.56%
|
|
|
Biomedicines
2 publications, 2.56%
|
|
|
Scientific Reports
2 publications, 2.56%
|
|
|
Discover Oncology
2 publications, 2.56%
|
|
|
iScience
2 publications, 2.56%
|
|
|
npj Precision Oncology
2 publications, 2.56%
|
|
|
Journal of Tissue Engineering
1 publication, 1.28%
|
|
|
Journal of Translational Medicine
1 publication, 1.28%
|
|
|
Seminars in Cancer Biology
1 publication, 1.28%
|
|
|
Hepatology International
1 publication, 1.28%
|
|
|
Liver Cancer
1 publication, 1.28%
|
|
|
Journal for ImmunoTherapy of Cancer
1 publication, 1.28%
|
|
|
bioRxiv
1 publication, 1.28%
|
|
|
Cellular and Molecular Gastroenterology and Hepatology
1 publication, 1.28%
|
|
|
Journal of Advanced Research
1 publication, 1.28%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 1.28%
|
|
|
Expert Review of Clinical Pharmacology
1 publication, 1.28%
|
|
|
Collagen and Leather
1 publication, 1.28%
|
|
|
ESMO Open
1 publication, 1.28%
|
|
|
International Immunopharmacology
1 publication, 1.28%
|
|
|
Urologic Oncology: Seminars and Original Investigations
1 publication, 1.28%
|
|
|
Immuno-Oncology Technology
1 publication, 1.28%
|
|
|
Biomolecules
1 publication, 1.28%
|
|
|
Critical Reviews in Oncology/Hematology
1 publication, 1.28%
|
|
|
Current Oncology Reports
1 publication, 1.28%
|
|
|
Acta Biomaterialia
1 publication, 1.28%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
14
16
18
20
|
|
|
Elsevier
19 publications, 24.36%
|
|
|
Springer Nature
17 publications, 21.79%
|
|
|
MDPI
13 publications, 16.67%
|
|
|
Frontiers Media S.A.
10 publications, 12.82%
|
|
|
SAGE
3 publications, 3.85%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 3.85%
|
|
|
Taylor & Francis
2 publications, 2.56%
|
|
|
Oxford University Press
2 publications, 2.56%
|
|
|
S. Karger AG
1 publication, 1.28%
|
|
|
BMJ
1 publication, 1.28%
|
|
|
Pharmaceutical Society of Japan
1 publication, 1.28%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 1.28%
|
|
|
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
1 publication, 1.28%
|
|
|
Wiley
1 publication, 1.28%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 1.28%
|
|
|
Baishideng Publishing Group
1 publication, 1.28%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.